Immunocytochemistry in the diagnosis of malignant melanoma.
The role of immunocytochemistry in the routine diagnosis of malignant melanoma is reviewed, with particular emphasis on the potential technical and pathological interpretive problems that may occur. Careful evaluation of the appropriate panel of markers is discussed, along with details of cross-reactivity of markers with tumours of non-melanocytic derivation. Future developments in immunocytochemistry within the field of proliferation indices assessments are highlighted.
Dermatopathology Department, St John's Dermatology Centre, St Thomas' Hospital, London, England, UK.
G
G
Orchard
E
E
Wilson Jones
D000906:Antibodies / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007382:Intermediate Filaments / Q000737:chemistry; D008545:Melanoma / Q000175:diagnosis*; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D009418:S100 Proteins / Q000032:analysis; D012878:Skin Neoplasms / Q000175:diagnosis*; D013869:Thiolester Hydrolases / Q000032:analysis; D043222:Ubiquitin Thiolesterase
D000906:Antibodies; D014408:Biomarkers, Tumor; D009418:S100 Proteins; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase; D010751:Phosphopyruvate Hydratase